3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow Boundless Bio, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer BBI-940, Fulvestrant - Breast Cancer, Metastatic Breast Cancer | Phase 1 | Terminated | Boundless Bio, Inc. | 8 | 2026-02-25 | 2026-08-19 |
| Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications BBI-825 - Solid Tumor | Phase 1 | Terminated | Boundless Bio, Inc. | 19 | 2024-03-28 | 2026-06-08 |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
Breast Neoplasms (1) · Histiocytoma, Malignant Fibrous (1) · Leiomyosarcoma (1) · Small Cell Lung Carcinoma (1) · Squamous Cell Carcinoma of Head and Neck (1) · Triple Negative Breast Neoplasms (1)
Erlotinib Hydrochloride (1) · Fulvestrant (1) · futibatinib (1)
United States (3)
Robert C. Doebele, MD, PhD (1) · Robert Doebele, MD (1) · Robert Doebele, MD, PhD (1)